He C - Search Results

1

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.

Qu YY, Sun Z, Han W, Zou Q, Xing N, Luo H, Zhang X, He C, Bian XJ, Cai J, Chen C, Wang Q, Ye DW. Qu YY, et al. Among authors: he c. J Immunother Cancer. 2022 May;10(5):e004427. doi: 10.1136/jitc-2021-004427. J Immunother Cancer. 2022. PMID: 35537782 Free PMC article. Clinical Trial.

2

Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.

Wang Z, Zhang Y, Liu Y, Wang L, Zhao L, Yang T, He C, Song Y, Gao Q. Wang Z, et al. Among authors: he c. J Immunother. 2014 Jan;37(1):43-50. doi: 10.1097/CJI.0000000000000005. J Immunother. 2014. PMID: 24316555

3

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer.

Ruan Q, Ding D, Wang B, He C, Ren X, Feng Z, Pang Z, Wang J, Zhang X, Tang H, Wang J, He Q, Lei Z, Liao Q, Luo J, Cui S. Ruan Q, et al. Among authors: he c, he q. Cancer Biol Med. 2021 Feb 15;18(1):308-317. doi: 10.20892/j.issn.2095-3941.2020.0125. Cancer Biol Med. 2021. PMID: 33628603 Free PMC article.

4

Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study.

Qu YY, Zhang HL, Guo H, Luo H, Zou Q, Xing N, Xia S, Sun Z, Zhang X, He C, Cai J, Zhang X, Wang Q, Ye DW. Qu YY, et al. Among authors: he c. Clin Cancer Res. 2021 Nov 1;27(21):5838-5846. doi: 10.1158/1078-0432.CCR-21-1698. Epub 2021 Aug 16. Clin Cancer Res. 2021. PMID: 34400414

5

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.

6

Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial.

Qin X, Ji D, Gu W, Han W, Luo H, Du C, Zou Q, Sun Z, He C, Zhu S, Chong T, Yao X, Wan B, Yang X, Bai A, Jin C, Zou J, Ye D. Qin X, et al. Among authors: he c. BMC Med. 2022 Mar 4;20(1):84. doi: 10.1186/s12916-022-02263-x. BMC Med. 2022. PMID: 35241087 Free PMC article. Clinical Trial.

7

Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).

Sheng X, Ye D, Zhou A, Yao X, Luo H, He Z, Wang Z, Zhao Y, Ji Z, Zou Q, He C, Guo J, Tu X, Liu Z, Shi B, Liu B, Chen P, Wei Q, Hu Z, Zhang Y, Jiang K, Zhou F, Wu D, Fu C, Li X, Wu B, Wang L, Qin S, Li G, Liu Y, Guo H, Chen K, Zhang D, Wang G, Ding L, Wang Y, Yuan X, Guo J. Sheng X, et al. Among authors: he c, he z. Eur J Cancer. 2023 Jan;178:205-215. doi: 10.1016/j.ejca.2022.10.025. Epub 2022 Nov 1. Eur J Cancer. 2023. PMID: 36459768 Free article. Clinical Trial.

8

Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.

Yang D, Ma Y, Zhao P, Ma J, He C. Yang D, et al. Among authors: he c. Biomed Pharmacother. 2019 Dec;120:109433. doi: 10.1016/j.biopha.2019.109433. Epub 2019 Sep 27. Biomed Pharmacother. 2019. PMID: 31568988 Free article.

9

HMMR is a downstream target of FOXM1 in enhancing proliferation and partial epithelial-to-mesenchymal transition of bladder cancer cells.

Yang D, Ma Y, Zhao P, Ma J, He C. Yang D, et al. Among authors: he c. Exp Cell Res. 2021 Nov 15;408(2):112860. doi: 10.1016/j.yexcr.2021.112860. Epub 2021 Oct 5. Exp Cell Res. 2021. PMID: 34624323

10

Combining Protein and miRNA Quantification for Bladder Cancer Analysis.

Duan R, Zhang Z, Zheng F, Wang L, Guo J, Zhang T, Dai X, Zhang S, Yang D, Kuang R, Wang G, He C, Hakeem A, Shu C, Yin P, Lou X, Zeng F, Liang H, Xia F. Duan R, et al. Among authors: he c. ACS Appl Mater Interfaces. 2017 Jul 19;9(28):23420-23427. doi: 10.1021/acsami.7b05639. Epub 2017 Jul 6. ACS Appl Mater Interfaces. 2017. PMID: 28636312

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11,844 results

Search Page